Skip to search formSkip to main contentSkip to account menu

CMA 676

Known as: CMA-676 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Gemtuzumab ozogamicingemtuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Treatment of CD33 positive refractory acute lymphoblastic leukemia with Mylotarg
Acute lymphoblastic leukemia (ALL) accounts for approximately 15 – 20% of all adult acute leukemias, and the incidence increases… 
2005
2005
Possible association between Budd‐Chiari syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia
Gemtuzumab ozogamicin (GO; CMA‐676; Mylotarg™) is a chemotherapeutic agent approved for the treatment of CD33‐positive acute… 
2003
2003
CMA-676: Mechanism of Action and Clinical Results
Investigators in Europe and North America have been involved in clinical trials of a new agent for the treatment of relapsed… 
Review
2002
Review
2002
Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia.
Gemtuzumab Ozogamicin (GO, CMA-676) is a monoclonal antibody against the cellular surface antigen CD33 conjugated with the… 
Review
2002
Review
2002
New drugs for therapy of AML
Several novel agents have emerged recently for therapy for acute myeloid leukemia (AML). Among these are drugs that specifically… 
Review
2002
Review
2002
Nursing implications of mylotarg: a novel antibody-targeted chemotherapy for CD33+ acute myeloid leukemia in first relapse.
PURPOSE/OBJECTIVES To review the nursing implications of gemtuzumab ozogamicin (Mylotarg(r), CMA-676, Wyeth Pharmaceuticals… 
2001
2001
Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein…
2000
2000
Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676).
The anti-CD33 monoclonal antibody linked to NAc-gamma calicheamicin gemtuzumab ozogamicin (CMA-676) was used to treat a patient… 
2000
2000
Molecular remission of Philadelphia/bcr‐abl‐positive acute myeloid leukaemia after treatment with anti‐CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA‐676)
The anti‐CD33 monoclonal antibody linked to NAc‐gamma calicheamicin gemtuzumab ozogamicin (CMA‐676) was used to treat a patient… 
2000
2000
Low incidence of hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (mylotarg™, cma-676)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)